Abstract
We studied the rate of progression of striatal dopamine transporter function in Parkinson's disease (PD). Eight patients with early PD without antiparkinsonian medication and 7 healthy volunteers were investigated with [18F]CFT positron emission tomography (PET). The PET scan was carried out twice at an approximate 2-year interval. The uptake of [18F]CFT was calculated as a region-cerebellum:cerebellum ratio at 180 to 210 minutes after injection. At the first PET scan, the [18F]CFT uptake in PD patients in the putamen was 1.45 +/- 0.45 (mean +/- SD) (42% of the control mean) and 2.43 +/- 0.59 in the caudate nucleus (76% of the control mean). The ratios declined by the time of the second PET scan, and the rate of annual decline of the baseline mean in PD patients was 13.1% in the putamen and 12.5% in the caudate nucleus. In controls, the corresponding figures were 2.1% for the putamen and 2.9% for the caudate nucleus. The decline in [18F]CFT uptake was significantly higher in PD patients than in controls. Thus, dopamine transporter ligands such as [18F]CFT seem to be sensitive markers for the rate of progression in PD.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antiparkinson Agents / therapeutic use
-
Brain / diagnostic imaging
-
Brain / metabolism*
-
Carrier Proteins / analysis*
-
Carrier Proteins / metabolism
-
Caudate Nucleus / diagnostic imaging
-
Caudate Nucleus / metabolism
-
Cerebellum / diagnostic imaging
-
Cerebellum / metabolism
-
Cocaine / analogs & derivatives*
-
Cocaine / pharmacokinetics
-
Disease Progression
-
Dopamine Plasma Membrane Transport Proteins
-
Dopamine Uptake Inhibitors / pharmacokinetics*
-
Female
-
Fluorine Radioisotopes* / pharmacokinetics
-
Humans
-
Male
-
Membrane Glycoproteins*
-
Membrane Transport Proteins*
-
Middle Aged
-
Nerve Tissue Proteins*
-
Parkinson Disease / diagnostic imaging*
-
Parkinson Disease / drug therapy
-
Parkinson Disease / physiopathology*
-
Putamen / diagnostic imaging
-
Putamen / metabolism
-
Time Factors
-
Tomography, Emission-Computed
Substances
-
Antiparkinson Agents
-
Carrier Proteins
-
Dopamine Plasma Membrane Transport Proteins
-
Dopamine Uptake Inhibitors
-
Fluorine Radioisotopes
-
Membrane Glycoproteins
-
Membrane Transport Proteins
-
Nerve Tissue Proteins
-
(1R-(exo,exo))-3-(4-fluorophenyl)-8-methyl-8- azabicyclo(3.2.1)octane-2-carboxylic acid, methyl ester
-
Cocaine